Medtronic’s BrainSense aDBS is a therapy intended to improve the quality of life for individuals living with Parkinson’s disease.

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions ...

Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain simulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...

Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson’s disease.

Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology, introducing aDBS for people living with Parkinson's.

The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice. Dr.

Dr. Helen Bronte-Stewart shows a Medtronic neurostimulator, the device implant that delivers adaptive Deep Brain Stimulation (aDBS) with electrical signals that adapt in response to the Parkinson ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain stimulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep ...